Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2013 May 1

PMID 23630663

Citations 40

Authors

Grit S Herter-Sprie

Heidi Greulich

Kwok-Kin Wong

Affiliations

Soon will be listed here.

Abstract

Despite the ongoing "war on cancer," cancer remains one of the major causes of human morbidity and mortality. A new paradigm of targeted therapies holds the most promise for the future, making identification of tumor-specific therapeutic targets of prime importance. ERBB2/HER2, best known for its role in breast cancer tumorigenesis, can be targeted by two types of pharmacological manipulation: antibody therapy against the extracellular receptor domain and small molecule compounds against the intracellular tyrosine kinase domain. Aberrant activation of ERBB2 by gene amplification has been shown to participate in the pathophysiology of breast, ovarian, gastric, colorectal, lung, brain, and head and neck tumors. However, the advent of next-generation sequencing technologies has enabled efficient identification of activating molecular alterations of ERBB2. In this review, we will focus on the functional role of these somatic mutations that cause ERBB2 receptor activation. We will additionally discuss the current preclinical and clinical therapeutic strategies for targeting mutationally activated ERBB2.

Citing Articles

Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma.

Qu M, Zhou L, Yan X, Li S, Wu X, Xu H Bladder (San Franc). 2023; 10:e21200012.

PMID: 38155921 PMC: 10752798. DOI: 10.14440/bladder.2023.871.

exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.

Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi S, VanderLaan P Transl Lung Cancer Res. 2023; 12(7):1590-1610.

PMID: 37577308 PMC: 10413034. DOI: 10.21037/tlcr-23-98.

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers.

Zheng Y, Zou J, Sun C, Peng F, Peng C Front Mol Biosci. 2023; 10:1165781.

PMID: 37251081 PMC: 10210145. DOI: 10.3389/fmolb.2023.1165781.

Deciphering the Impact of Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches.

Bontoux C, Benzaquen J, Hofman V, Heeke S, Hannetel P, Capela-Brosseau-Laborde P J Pers Med. 2022; 12(10).

PMID: 36294789 PMC: 9605102. DOI: 10.3390/jpm12101651.

Bispecific Antibodies for IFN-β Delivery to ErbB2 Tumors.

Rybchenko V, Panina A, Aliev T, Solopova O, Balabashin D, Novoseletsky V Biomolecules. 2021; 11(12).

PMID: 34944558 PMC: 8699518. DOI: 10.3390/biom11121915.

References

Herbst R, Davies A, Natale R, Dang T, Schiller J, Garland L . Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007; 13(20):6175-81. DOI: 10.1158/1078-0432.CCR-07-0460. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Schindler T, Bornmann W, Pellicena P, Miller W, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289(5486):1938-42. DOI: 10.1126/science.289.5486.1938. View

Arcila M, Chaft J, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M . Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012; 18(18):4910-8. PMC: 3865806. DOI: 10.1158/1078-0432.CCR-12-0912. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Fan Y, Wong L, Ding J, Spiridonov N, Johnson R, Johnson G . Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem. 2007; 283(3):1588-1596. DOI: 10.1074/jbc.M708116200. View

Carraway 3rd K, Sliwkowski M, Akita R, Platko J, Guy P, Nuijens A . The erbB3 gene product is a receptor for heregulin. J Biol Chem. 1994; 269(19):14303-6. View

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus S . Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther. 2011; 10(8):1367-74. PMC: 3836594. DOI: 10.1158/1535-7163.MCT-10-0991. View

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini P . Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res. 2010; 16(9):2688-95. PMC: 3243489. DOI: 10.1158/1078-0432.CCR-09-3407. View

10.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

11.

Tortora G . Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr. 2011; 2011(43):95-8. DOI: 10.1093/jncimonographs/lgr026. View

12.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

13.

Di Fiore P, PIERCE J, Kraus M, Segatto O, King C, Aaronson S . erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237(4811):178-82. DOI: 10.1126/science.2885917. View

14.

Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F . HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res. 2003; 9(10 Pt 1):3645-52. View

15.

Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt K, Liniker E . The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 2007; 26(34):5023-7. DOI: 10.1038/sj.onc.1210292. View

16.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

17.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Aktan G . Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012; 30(21):2585-92. DOI: 10.1200/JCO.2011.35.6725. View

18.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

19.

Molina M, Saez R, Ramsey E, Garcia-Barchino M, Rojo F, Evans A . NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002; 8(2):347-53. View

20.

Wong K, Fracasso P, Bukowski R, Lynch T, Munster P, Shapiro G . A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009; 15(7):2552-8. DOI: 10.1158/1078-0432.CCR-08-1978. View